Which has better valuation & earnings, EOLS or PGEN?

Evolus has higher revenue and earnings than Precigen. Evolus is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evolus $297.18M 1.54 -$51.64M -$0.67 N/A Precigen $9.68M 209.93 -$250.64M -$1.18 N/A

Is EOLS or PGEN more profitable?

Evolus has a net margin of -14.39% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat Evolus' return on equity. Company Net Margins Return on Equity Return on Assets Evolus -14.39% N/A -19.03% Precigen -646.99% 717.50% 58.48%

Evolus (EOLS) Competitors

$6.94 -0.19 (-2.66%)

Closing price 04:00 PM Eastern

Extended Trading

$6.94 -0.01 (-0.07%)

As of 04:59 PM Eastern

Compare

EOLS vs. IOVA, AMLX, PGEN, RXRX, and CMPS

Should you buy Evolus stock or one of its competitors? MarketBeat compares Evolus with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Evolus include Iovance Biotherapeutics (IOVA), Amylyx Pharmaceuticals (AMLX), Precigen (PGEN), Recursion Pharmaceuticals (RXRX), and Compass Pathways (CMPS). These companies are all part of the "pharmaceutical products" industry.

How does Evolus compare to Iovance Biotherapeutics?

Iovance Biotherapeutics (NASDAQ:IOVA) and Evolus (NASDAQ:EOLS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.

Iovance Biotherapeutics has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market. Comparatively, Evolus has a beta of 1.34, meaning that its stock price is 34% more volatile than the broader market.

Evolus has higher revenue and earnings than Iovance Biotherapeutics. Evolus is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iovance Biotherapeutics	$263.50M	7.05	-$390.98M	-$0.95	N/A
Evolus	$297.18M	1.54	-$51.64M	-$0.67	N/A

In the previous week, Iovance Biotherapeutics had 3 more articles in the media than Evolus. MarketBeat recorded 4 mentions for Iovance Biotherapeutics and 1 mentions for Evolus. Evolus' average media sentiment score of 1.89 beat Iovance Biotherapeutics' score of 0.96 indicating that Evolus is being referred to more favorably in the news media.

Company	Overall Sentiment
Iovance Biotherapeutics	Positive
Evolus	Very Positive

Iovance Biotherapeutics presently has a consensus price target of $8.43, suggesting a potential upside of 102.61%. Evolus has a consensus price target of $16.00, suggesting a potential upside of 130.55%. Given Evolus' stronger consensus rating and higher probable upside, analysts clearly believe Evolus is more favorable than Iovance Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iovance Biotherapeutics	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30
Evolus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

77.0% of Iovance Biotherapeutics shares are held by institutional investors. Comparatively, 90.7% of Evolus shares are held by institutional investors. 7.8% of Iovance Biotherapeutics shares are held by insiders. Comparatively, 5.0% of Evolus shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Evolus has a net margin of -14.39% compared to Iovance Biotherapeutics' net margin of -123.92%. Evolus' return on equity of 0.00% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iovance Biotherapeutics	-123.92%	-50.17%	-38.77%
Evolus	-14.39%	N/A	-19.03%

Summary

Evolus beats Iovance Biotherapeutics on 11 of the 16 factors compared between the two stocks.

How does Evolus compare to Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals (NASDAQ:AMLX) and Evolus (NASDAQ:EOLS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings.

Evolus has higher revenue and earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Evolus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	$87.37M	22.84	-$144.74M	-$1.50	N/A
Evolus	$297.18M	1.54	-$51.64M	-$0.67	N/A

Amylyx Pharmaceuticals has a net margin of 0.00% compared to Evolus' net margin of -14.39%. Evolus' return on equity of 0.00% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-55.69%	-50.73%
Evolus	-14.39%	N/A	-19.03%

Amylyx Pharmaceuticals presently has a consensus price target of $24.25, indicating a potential upside of 35.13%. Evolus has a consensus price target of $16.00, indicating a potential upside of 130.55%. Given Evolus' higher probable upside, analysts clearly believe Evolus is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Evolus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 90.7% of Evolus shares are owned by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are owned by insiders. Comparatively, 5.0% of Evolus shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Amylyx Pharmaceuticals has a beta of -0.16, indicating that its share price is 116% less volatile than the broader market. Comparatively, Evolus has a beta of 1.34, indicating that its share price is 34% more volatile than the broader market.

In the previous week, Amylyx Pharmaceuticals had 4 more articles in the media than Evolus. MarketBeat recorded 5 mentions for Amylyx Pharmaceuticals and 1 mentions for Evolus. Evolus' average media sentiment score of 1.89 beat Amylyx Pharmaceuticals' score of 0.58 indicating that Evolus is being referred to more favorably in the news media.

Company	Overall Sentiment
Amylyx Pharmaceuticals	Positive
Evolus	Very Positive

Summary

Evolus beats Amylyx Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Evolus compare to Precigen?

Evolus (NASDAQ:EOLS) and Precigen (NASDAQ:PGEN) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership, media sentiment and risk.

Evolus has higher revenue and earnings than Precigen. Evolus is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evolus	$297.18M	1.54	-$51.64M	-$0.67	N/A
Precigen	$9.68M	209.93	-$250.64M	-$1.18	N/A

In the previous week, Precigen had 3 more articles in the media than Evolus. MarketBeat recorded 4 mentions for Precigen and 1 mentions for Evolus. Evolus' average media sentiment score of 1.89 beat Precigen's score of 1.69 indicating that Evolus is being referred to more favorably in the media.

Company	Overall Sentiment
Evolus	Very Positive
Precigen	Very Positive

Evolus has a net margin of -14.39% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat Evolus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evolus	-14.39%	N/A	-19.03%
Precigen	-646.99%	717.50%	58.48%

90.7% of Evolus shares are owned by institutional investors. Comparatively, 33.5% of Precigen shares are owned by institutional investors. 5.0% of Evolus shares are owned by insiders. Comparatively, 41.4% of Precigen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Evolus presently has a consensus target price of $16.00, suggesting a potential upside of 130.55%. Precigen has a consensus target price of $12.50, suggesting a potential upside of 119.30%. Given Evolus' stronger consensus rating and higher probable upside, equities analysts plainly believe Evolus is more favorable than Precigen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evolus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Precigen	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Evolus has a beta of 1.34, meaning that its share price is 34% more volatile than the broader market. Comparatively, Precigen has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market.

Summary

Evolus beats Precigen on 10 of the 16 factors compared between the two stocks.

How does Evolus compare to Recursion Pharmaceuticals?

Evolus (NASDAQ:EOLS) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk and valuation.

Evolus has higher revenue and earnings than Recursion Pharmaceuticals. Evolus is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evolus	$297.18M	1.54	-$51.64M	-$0.67	N/A
Recursion Pharmaceuticals	$74.68M	26.04	-$644.76M	-$1.20	N/A

90.7% of Evolus shares are held by institutional investors. Comparatively, 89.1% of Recursion Pharmaceuticals shares are held by institutional investors. 5.0% of Evolus shares are held by insiders. Comparatively, 6.7% of Recursion Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Evolus currently has a consensus target price of $16.00, suggesting a potential upside of 130.55%. Recursion Pharmaceuticals has a consensus target price of $8.10, suggesting a potential upside of 120.71%. Given Evolus' stronger consensus rating and higher probable upside, research analysts clearly believe Evolus is more favorable than Recursion Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evolus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Recursion Pharmaceuticals had 4 more articles in the media than Evolus. MarketBeat recorded 5 mentions for Recursion Pharmaceuticals and 1 mentions for Evolus. Evolus' average media sentiment score of 1.89 beat Recursion Pharmaceuticals' score of 0.99 indicating that Evolus is being referred to more favorably in the media.

Company	Overall Sentiment
Evolus	Very Positive
Recursion Pharmaceuticals	Positive

Evolus has a net margin of -14.39% compared to Recursion Pharmaceuticals' net margin of -842.95%. Evolus' return on equity of 0.00% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evolus	-14.39%	N/A	-19.03%
Recursion Pharmaceuticals	-842.95%	-54.33%	-40.60%

Evolus has a beta of 1.34, meaning that its share price is 34% more volatile than the broader market. Comparatively, Recursion Pharmaceuticals has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market.

Summary

Evolus beats Recursion Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Evolus compare to Compass Pathways?

Compass Pathways (NASDAQ:CMPS) and Evolus (NASDAQ:EOLS) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

In the previous week, Compass Pathways had 3 more articles in the media than Evolus. MarketBeat recorded 4 mentions for Compass Pathways and 1 mentions for Evolus. Evolus' average media sentiment score of 1.89 beat Compass Pathways' score of 0.58 indicating that Evolus is being referred to more favorably in the news media.

Company	Overall Sentiment
Compass Pathways	Positive
Evolus	Very Positive

Compass Pathways has a net margin of 0.00% compared to Evolus' net margin of -14.39%. Evolus' return on equity of 0.00% beat Compass Pathways' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Pathways	N/A	-31.07%	-11.40%
Evolus	-14.39%	N/A	-19.03%

Compass Pathways currently has a consensus target price of $23.10, indicating a potential upside of 63.25%. Evolus has a consensus target price of $16.00, indicating a potential upside of 130.55%. Given Evolus' higher probable upside, analysts plainly believe Evolus is more favorable than Compass Pathways.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Pathways	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Evolus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Evolus has higher revenue and earnings than Compass Pathways. Evolus is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Pathways	N/A	N/A	-$287.86M	-$3.15	N/A
Evolus	$297.18M	1.54	-$51.64M	-$0.67	N/A

46.2% of Compass Pathways shares are owned by institutional investors. Comparatively, 90.7% of Evolus shares are owned by institutional investors. 2.8% of Compass Pathways shares are owned by company insiders. Comparatively, 5.0% of Evolus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Compass Pathways has a beta of 2.5, meaning that its share price is 150% more volatile than the broader market. Comparatively, Evolus has a beta of 1.34, meaning that its share price is 34% more volatile than the broader market.

Summary

Compass Pathways and Evolus tied by winning 8 of the 16 factors compared between the two stocks.

Get Evolus News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EOLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EOLS vs. The Competition

Export

Metric	Evolus	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$469.54M	$8.64B	$6.87B	$12.45B
Dividend Yield	N/A	2.52%	2.67%	6.16%
P/E Ratio	-10.36	15.85	27.51	24.87
Price / Sales	1.54	7.22	540.69	102.84
Price / Cash	N/A	17.76	48.53	58.59
Price / Book	-19.28	3.42	11.01	6.54
Net Income	-$51.64M	$226.25M	$3.57B	$336.70M
7 Day Performance	2.97%	2.27%	2.56%	3.31%
1 Month Performance	5.79%	-4.20%	0.89%	1.68%
1 Year Performance	-24.65%	0.15%	36.84%	31.96%

Evolus Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EOLS Evolus	2.7527 of 5 stars	$6.94 -2.7%	$16.00 +130.5%	-22.0%	$469.54M	$297.18M	N/A	170	Positive News
IOVA Iovance Biotherapeutics	2.3095 of 5 stars	$4.06 +3.8%	$8.43 +107.6%	+149.1%	$1.75B	$263.50M	N/A	500	Analyst Revision
AMLX Amylyx Pharmaceuticals	3.8344 of 5 stars	$16.28 +3.9%	$23.00 +41.3%	+195.4%	$1.74B	$87.37M	N/A	200
PGEN Precigen	3.4384 of 5 stars	$5.38 +11.6%	$12.50 +132.3%	+316.9%	$1.72B	$9.68M	N/A	190	Positive News
RXRX Recursion Pharmaceuticals	2.951 of 5 stars	$3.18 -1.5%	$8.10 +154.7%	-26.6%	$1.71B	$74.68M	N/A	400

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EOLS) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Evolus (EOLS) Competitors

EOLS vs. IOVA, AMLX, PGEN, RXRX, and CMPS

How does Evolus compare to Iovance Biotherapeutics?

Summary

How does Evolus compare to Amylyx Pharmaceuticals?

Summary

How does Evolus compare to Precigen?

Summary

How does Evolus compare to Recursion Pharmaceuticals?

Summary

How does Evolus compare to Compass Pathways?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EOLS vs. The Competition

Evolus Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Evolus (EOLS) Competitors

EOLS vs. IOVA, AMLX, PGEN, RXRX, and CMPS

How does Evolus compare to Iovance Biotherapeutics?

Which has more risk & volatility, IOVA or EOLS?

Which has stronger earnings & valuation, IOVA or EOLS?

Does the media prefer IOVA or EOLS?

Do analysts prefer IOVA or EOLS?

Do insiders & institutionals hold more shares of IOVA or EOLS?

Is IOVA or EOLS more profitable?

Summary

How does Evolus compare to Amylyx Pharmaceuticals?

Which has higher valuation and earnings, AMLX or EOLS?

Is AMLX or EOLS more profitable?

Do analysts prefer AMLX or EOLS?

Do insiders and institutionals believe in AMLX or EOLS?

Which has more risk and volatility, AMLX or EOLS?

Does the media prefer AMLX or EOLS?

Summary

How does Evolus compare to Precigen?

Which has better valuation & earnings, EOLS or PGEN?

Does the media refer more to EOLS or PGEN?

Is EOLS or PGEN more profitable?

Do insiders & institutionals hold more shares of EOLS or PGEN?

Do analysts recommend EOLS or PGEN?

Which has more risk and volatility, EOLS or PGEN?

Summary

How does Evolus compare to Recursion Pharmaceuticals?

Which has stronger valuation & earnings, EOLS or RXRX?

Do institutionals and insiders hold more shares of EOLS or RXRX?

Do analysts recommend EOLS or RXRX?

Does the media refer more to EOLS or RXRX?

Is EOLS or RXRX more profitable?

Which has more risk and volatility, EOLS or RXRX?

Summary

How does Evolus compare to Compass Pathways?

Does the media prefer CMPS or EOLS?

Is CMPS or EOLS more profitable?

Do analysts rate CMPS or EOLS?

Which has higher earnings & valuation, CMPS or EOLS?

Do insiders and institutionals believe in CMPS or EOLS?

Which has more risk and volatility, CMPS or EOLS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EOLS vs. The Competition

Evolus Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools